Explore a selection of our essential drug information below, or:
Identification
- Summary
Sodium sulfate is an agent used for bowel cleansing prior to colonoscopy or barium enema X-ray examination.
- Brand Names
- Bi-peglyte, Colyte, Gavilyte-C, Gavilyte-G, Golytely, Moviprep, Peglyte, Plenvu, Suflave, Suprep Bowel Prep Kit
- Generic Name
- Sodium sulfate
- DrugBank Accession Number
- DB09472
- Background
Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions.
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
Structure for Sodium sulfate (DB09472)
- Weight
- Average: 142.042
Monoisotopic: 141.931268528 - Chemical Formula
- Na2O4S
- Synonyms
- Anhydrous sodium sulfate
- Sodium sulfate anhydrous
- Sodium sulfate, anhydrous
- Sodium sulphate anhydrous
- Sodium sulphate, anhydrous
- Sulfuric acid disodium salt, anhydrous
Pharmacology
- Indication
indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Induces catharsis by the osmotic effects of the unabsorbed sulfate salts and polyethylene glycol (PEG) in the GI tract. Specifically, sulfate salts provide sulfate anions, which are poorly absorbed, and PEG, which is primarily unabsorbed, causes water to be retained in the GI tract resulting in watery diarrhea.
- Mechanism of action
MoviPrep produces a watery stool leading to cleansing of the colon. The osmotic activity of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, when taken with 1 liter of additional clear fluid, usually results in no net absorption or excretion of ions or water.
Target Actions Organism ACarbonic anhydrase 2 inhibitorHumans ACarbonic anhydrase 1 inhibitorHumans - Absorption
Absorption of sodium sulfate after ingestion in rats was investigated. 35)S-Radioactivity excreted in urine during 24 hr indicated almost complete absorption from GI tract. Determination in serum 2 hr after admin revealed 3-fold increase in sulfate concentration rapid and almost complete absorption of inorganic sulfate occurs after oral admin in rats.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Rectal effluent if unabsorbed sulfates ; urine (predominant route for absorbed sulfates )
- Half-life
Serum sulfate: 8.5 hours
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Mouse LD50 (Oral): 5989mg/kg Mouse LDLo (Intravenous): 1220mg/kg Rabbit LD50 (Intravenous):1220mg/kg
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Acetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Sodium sulfate. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium sulfate decahydrate 0YPR65R21J 7727-73-3 RSIJVJUOQBWMIM-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Sulfate ion ionic 7IS9N8KPMG 14808-79-8 QAOWNCQODCNURD-UHFFFAOYSA-L - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bqcell Revirgin Gung Tablet 0.235 g/1 Enteral; Vaginal Dermabqcell Co., Ltd. 2022-04-09 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bi-peglyte Sodium sulfate (5.74 g / sachet) + Bisacodyl (5 mg / tab) + Polyethylene glycol (59.55 g / sachet) + Potassium chloride (0.76 g / sachet) + Sodium bicarbonate (1.69 g / sachet) + Sodium chloride (1.46 g / sachet) Kit; Powder, for solution; Tablet, delayed release Oral Pendopharm Division Of Pharmascience Inc 2010-06-06 Not applicable Canada 
Clenz-Lyte Sodium sulfate (22.74 g/4L) + Polyethylene glycol (236 g/4L) + Potassium chloride (2.97 g/4L) + Sodium bicarbonate (6.74 g/4L) + Sodium chloride (5.86 g/4L) Powder, for solution Nasogastric; Oral Paddock Laboratories, Inc. 2010-06-07 2010-06-07 US ColPrep Kit Sodium sulfate decahydrate (17.5 g/22.7g) + Magnesium sulfate (1.6 g/22.7g) + Potassium sulfate (3.13 g/22.7g) Powder, for solution Oral KVK-Tech, Inc. 2016-12-27 2019-01-24 US Colyte Sodium sulfate decahydrate (21.5 g/3.785L) + Polyethylene glycol (227.1 g/3.785L) + Potassium chloride (2.82 g/3.785L) + Sodium bicarbonate (6.36 g/3.785L) + Sodium chloride (5.53 g/3.785L) Powder, for solution Nasogastric; Oral Alaven Pharmaceutical 2010-09-01 2016-05-31 US Colyte Sodium sulfate (81.2 mg / g) + Polyethylene glycol (857.69 mg / g) + Potassium chloride (10.65 mg / g) + Sodium bicarbonate (24.02 mg / g) + Sodium chloride (20.87 mg / g) Powder, for solution Nasogastric; Oral Pendopharm Division Of Pharmascience Inc 1986-12-31 Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bqcell Revirgin Gung Sodium sulfate decahydrate (0.235 g/1) Tablet Enteral; Vaginal Dermabqcell Co., Ltd. 2022-04-09 Not applicable US Sodium polysulthionate and folic acid Sodium sulfate decahydrate (8 mg/1) + Folic acid (1 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1) Capsule Oral Solubiomix 2016-08-24 2017-10-16 US Sodium polysulthionate, 5-methyltetrahydrofolate Sodium sulfate decahydrate (2 g/100g) + Levomefolic acid (.125 g/100g) + Octasulfur (97 g/100g) + Sodium thiosulfate pentahydrate (.45 g/100g) Powder Oral; Topical Solubiomix 2015-07-21 2016-01-12 US Sodium Polysulthionate, 5-mthf Sodium sulfate decahydrate (8 mg/1) + 5-methyltetrahydrofolic acid (.5 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1) Capsule Oral Solubiomix 2016-01-09 2016-01-12 US Xizflus Sodium sulfate decahydrate (2 g/100g) + 5-methyltetrahydrofolic acid (.125 g/100g) + Octasulfur (97 g/100g) + Sodium thiosulfate pentahydrate (.45 g/100g) Powder Oral; Topical Basiem 2015-07-14 2016-01-12 US
Categories
- ATC Codes
- A06AD13 — Sodium sulfate
- A06AD — Osmotically acting laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal sulfates
- Direct Parent
- Alkali metal sulfates
- Alternative Parents
- Inorganic sodium salts / Inorganic oxides
- Substituents
- Alkali metal sulfate / Inorganic oxide / Inorganic salt / Inorganic sodium salt
- Molecular Framework
- Not Available
- External Descriptors
- inorganic sodium salt (CHEBI:32149)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 36KCS0R750
- CAS number
- 7757-82-6
- InChI Key
- PMZURENOXWZQFD-UHFFFAOYSA-L
- InChI
- InChI=1S/2Na.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2
- IUPAC Name
- disodium sulfate
- SMILES
- [Na+].[Na+].[O-]S([O-])(=O)=O
References
- General References
- Morris ME, Levy G: Serum concentration and renal excretion by normal adults of inorganic sulfate after acetaminophen, ascorbic acid, or sodium sulfate. Clin Pharmacol Ther. 1983 Apr;33(4):529-36. [Article]
- Cocchetto DM, Levy G: Absorption of orally administered sodium sulfate in humans. J Pharm Sci. 1981 Mar;70(3):331-3. [Article]
- Pubchem [Link]
- DRUGS.COM [Link]
- DAILYMED [Link]
- ChemIDplus [Link]
- inChem [Link]
- External Links
- KEGG Drug
- D01732
- KEGG Compound
- C13199
- PubChem Compound
- 24436
- PubChem Substance
- 347827857
- ChemSpider
- 22844
- BindingDB
- 50101993
- 1299926
- ChEBI
- 32149
- ChEMBL
- CHEMBL233406
- Wikipedia
- Sodium_sulfate
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Bowel preparation therapy 1 somestatus stop reason just information to hide Not Available Completed Not Available Colon Adenomas / Colon Cancer / Colon Cancer, Rectal Cancer / Colon Polyps 1 somestatus stop reason just information to hide Not Available Completed Not Available Colon Cancer / Colon Cleansing / Colonic Diseases 1 somestatus stop reason just information to hide Not Available Completed Not Available Ease of Bowel Preparation and Patient Tolerability / Efficacy of Bowel Preparation 1 somestatus stop reason just information to hide Not Available Completed Not Available Effectiveness of SMS to Fix PC Interval 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit; powder, for solution; tablet, delayed release Oral Tablet Enteral; Vaginal 0.235 g/1 Powder, for solution Nasogastric Liquid Oral Granule, for solution Oral 64 g Powder, for solution Nasogastric; Oral Kit Oral Kit; solution Oral Tablet, effervescent Oral Powder Oral 238.33 g Kit; powder, for solution Oral Powder, for solution Oral 7.54 g Powder, for solution Oral Solution Oral Powder Oral Solution, concentrate Oral Tablet Oral Granule, effervescent Oral 2.86 g Capsule Oral Powder Oral; Topical - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7169381 No 2007-01-30 2024-09-01 US US7658914 No 2010-02-09 2024-09-01 US US6946149 No 2005-09-20 2023-03-07 US US9326969 No 2016-05-03 2033-09-10 US US9592252 No 2017-03-14 2032-08-11 US US9707297 No 2017-07-18 2033-09-10 US US8999313 No 2015-04-07 2033-09-10 US US10016504 No 2018-07-10 2033-09-10 US US10646512 No 2020-05-12 2032-03-25 US US10792306 No 2020-10-06 2032-03-09 US US10780112 No 2020-09-22 2032-03-09 US US10143656 No 2018-12-04 2037-08-04 US US10918723 No 2021-02-16 2033-09-10 US US11033498 No 2021-06-15 2037-08-04 US US11382864 No 2017-08-04 2037-08-04 US US11529368 No 2012-03-09 2032-03-09 US US11638697 No 2017-08-04 2037-08-04 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.84 Chemaxon pKa (Strongest Acidic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.53 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0006-0900000000-1f5f53c7d5c9bceafb1c - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 100.205734 predictedDeepCCS 1.0 (2019) [M+H]+ 103.26146 predictedDeepCCS 1.0 (2019) [M+Na]+ 112.57707 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Catalyzes the reversible hydration of carbon dioxide (PubMed:11327835, PubMed:11802772, PubMed:11831900, PubMed:12056894, PubMed:12171926, PubMed:1336460, PubMed:14736236, PubMed:15300855, PubMed:15453828, PubMed:15667203, PubMed:15865431, PubMed:16106378, PubMed:16214338, PubMed:16290146, PubMed:16686544, PubMed:16759856, PubMed:16807956, PubMed:17127057, PubMed:17251017, PubMed:17314045, PubMed:17330962, PubMed:17346964, PubMed:17540563, PubMed:17588751, PubMed:17705204, PubMed:18024029, PubMed:18162396, PubMed:18266323, PubMed:18374572, PubMed:18481843, PubMed:18618712, PubMed:18640037, PubMed:18942852, PubMed:1909891, PubMed:1910042, PubMed:19170619, PubMed:19186056, PubMed:19206230, PubMed:19520834, PubMed:19778001, PubMed:7761440, PubMed:7901850, PubMed:8218160, PubMed:8262987, PubMed:8399159, PubMed:8451242, PubMed:8485129, PubMed:8639494, PubMed:9265618, PubMed:9398308). Can also hydrate cyanamide to urea (PubMed:10550681, PubMed:11015219). Stimulates the chloride-bicarbonate exchange activity of SLC26A6 (PubMed:15990874). Essential for bone resorption and osteoclast differentiation (PubMed:15300855). Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption
- Specific Function
- Arylesterase activity
- Gene Name
- CA2
- Uniprot ID
- P00918
- Uniprot Name
- Carbonic anhydrase 2
- Molecular Weight
- 29245.895 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Catalyzes the reversible hydration of carbon dioxide (PubMed:10550681, PubMed:16506782, PubMed:16686544, PubMed:16807956, PubMed:17127057, PubMed:17314045, PubMed:17407288, PubMed:18618712, PubMed:19186056, PubMed:19206230). Can hydrate cyanamide to urea (PubMed:10550681)
- Specific Function
- Arylesterase activity
- Gene Name
- CA1
- Uniprot ID
- P00915
- Uniprot Name
- Carbonic anhydrase 1
- Molecular Weight
- 28870.0 Da
References
Drug created at November 30, 2015 19:10 / Updated at January 09, 2021 18:41